FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906744624> ?p ?o ?g. }

• W2906744624 endingPage "583" @default.
• W2906744624 startingPage "583" @default.
• W2906744624 abstract "Abstract Rationale: The BTK inhibitor ibrutinib has proved to be highly effective in both treatment naїve and refractory or relapsed CLL patients. In contrast to most other therapeutic options, where unmutated IGVH correlates with adverse prognosis, response to ibrutinib is independent of IGVH mutation status. This compulsorily raises the question why CLL cells with an unmutated IGVH are equally susceptible to BTK inhibition. One key aspect might be understanding the global (phospho)proteome of UM-CLL and M-CLL cells which has not been investigated so far. Methods: We performed a comprehensive proteomics and phosphopreoteomics analysis of 14 CLL samples with unmutated or mutated IgVH using quantitative mass spectrometry (MS). ITRAQ labelling and TiO2 enrichment/HILIC fractionation were utilized for this approach. Results: Altogether we identified 9184 phosphopeptides corresponding to 2854 proteins. We found the typical pS:pT:pY ratio, with 89% of all detected phosphopeptides containing a phosphorylated serine (pS), 10% a phosphorylated threonine (pT) and 1% a phosphorylated tyrosine (pY) in CLL samples. Strikingly, UM-CLL showed a higher basal phosphorylation level than M-CLL samples with significantly higher phosphorylation of 92 out of 102 identified proteins (P<0.05) Interestingly, ibrutinib reverted this phosphorylation pattern predominantly in UM-CLL but not M-CLL samples and led to a shift of the ratio towards phosphotyrosine in UM-CLL (pS:pT:pY in %: 30:9:61) but not in M-CLL (pS:pT:pY: 78:7:15). Most of the indentified phosphopeptides clustered in pathways that regulate migration and motility and cell survival and death. Regarding the BCR pathway, we identified known and novel p-sites: Lyn (8 sites), PIK3AP1 (5), PLCG2 (5), Syk (4), BLK (4), PIK3R4 (2), LCK (2), BTK (1), PIK3C2B (1), PIK3C3 (1), PIK3CD (1). In this context a novel molecule, MARCKS attracted our attention. We identified three different p-sites (S101, T150 and S170) which were differentially phosphorylated in M-CLL and UM-CLL. Moreover, our proteome approach revealed distinct expression levels of 38 proteins out of 3466 isolated proteins between the two groups (1,5-fold changes; P<0.01), among them MARCKS. Expression of MARCKS was significantly higher in M-CLL samples. MARCKS, a PKC substrate, was shown to play a critical role in invasiveness and metastasis of various cancer types, but its role in CLL is unclear. Since MARCKS has not been associated with CLL, we proved our findings from MS in a larger cohort of CLL patients both on protein level (n=36) and on transcription level (n=337). Strikingly, shorter PFS of CLL patients (n=337) undergoing chemoimmunotherapy correlates with low expression of MARCKS independently of the mutational status. We further investigated the cellular function of MARCKS in CLL cells utilizing CRISPR/Cas9 to generate KO cells. We were able to show that MARCKS regulates migration towards CXCL12 and that a loss of MARCKS leads to significantly increased migration. As MARCKS is upstream of AKT at the plasma membrane, we wondered if its expression might be relevant for AKT signalling. Importantly, we found that AKT phosphorylation (S473) was significantly upregulated in MARCKS KO cells indicating that MARCKS is involved in AKT regulation. Since MARCKS seems to be involved in tumor microenvironment (TME) interaction, we determined the influence of TME stimuli on MARCKS regulation. Interestingly, MARCKS was upregulated by CD40:CD40L interaction but phosphorylated upon BCR stimulation in both M-CLL and UM-CLL as assessed by immunoblot. Furthermore, we identified MARCKS to be targeted by ibrutinib, as phosphorylation at S170 was reduced upon ibrutinib treatment. Conclusion: For the first time we could show a comprehensive picture of the phosphoproteome and proteome of UM-CLL and M-CLL samples. Strikingly, the basal phosphorylation level was significantly higher in UM-CLL and was more susceptible to ibrutinib treatment. Our findings reveal a relevant association of MARCKS expression with CLL prognosis, supported by the functional evidence that MARCKS acts upstream as novel modulator of AKT signalling and controls migration towards CXCL12. These data indicate that MARCKS is a novel and relevant target of ibrutinib especially in the context of the TME. Disclosures Bahlo: Roche: Honoraria, Other: Travel Grants. Fischer:Roche: Other: Travel support. Wendtner:Roche: Consultancy, Honoraria, Other: travel support, Research Funding; Janssen: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Genetech: Consultancy, Honoraria, Other: travel support, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Other: travel support, Research Funding; Abbvie: Consultancy, Honoraria, Other: travel support, Research Funding; Mundipharma: Consultancy, Honoraria, Research Funding; MorphoSys: Consultancy, Honoraria, Other: travel support, Research Funding; Pharmacyclics: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding. Stilgenbauer:Pharmcyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genzyme: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Mundipharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Hoffmann La-Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Hallek:Pharmacyclics: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Mundipharma: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Roche: Honoraria, Research Funding." @default.
• W2906744624 created "2019-01-11" @default.
• W2906744624 creator A5018804552 @default.
• W2906744624 creator A5019866348 @default.
• W2906744624 creator A5023752156 @default.
• W2906744624 creator A5024254750 @default.
• W2906744624 creator A5035734503 @default.
• W2906744624 creator A5035800074 @default.
• W2906744624 creator A5041621560 @default.
• W2906744624 creator A5043791269 @default.
• W2906744624 creator A5048054782 @default.
• W2906744624 creator A5052133938 @default.
• W2906744624 creator A5061682665 @default.
• W2906744624 creator A5067592137 @default.
• W2906744624 creator A5067845923 @default.
• W2906744624 creator A5073907626 @default.
• W2906744624 creator A5076077834 @default.
• W2906744624 creator A5086557136 @default.
• W2906744624 date "2018-11-29" @default.
• W2906744624 modified "2023-10-18" @default.
• W2906744624 title "Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL" @default.
• W2906744624 doi "https://doi.org/10.1182/blood-2018-99-118235" @default.
• W2906744624 hasPublicationYear "2018" @default.
• W2906744624 type Work @default.
• W2906744624 sameAs 2906744624 @default.
• W2906744624 citedByCount "0" @default.
• W2906744624 crossrefType "journal-article" @default.
• W2906744624 hasAuthorship W2906744624A5018804552 @default.
• W2906744624 hasAuthorship W2906744624A5019866348 @default.
• W2906744624 hasAuthorship W2906744624A5023752156 @default.
• W2906744624 hasAuthorship W2906744624A5024254750 @default.
• W2906744624 hasAuthorship W2906744624A5035734503 @default.
• W2906744624 hasAuthorship W2906744624A5035800074 @default.
• W2906744624 hasAuthorship W2906744624A5041621560 @default.
• W2906744624 hasAuthorship W2906744624A5043791269 @default.
• W2906744624 hasAuthorship W2906744624A5048054782 @default.
• W2906744624 hasAuthorship W2906744624A5052133938 @default.
• W2906744624 hasAuthorship W2906744624A5061682665 @default.
• W2906744624 hasAuthorship W2906744624A5067592137 @default.
• W2906744624 hasAuthorship W2906744624A5067845923 @default.
• W2906744624 hasAuthorship W2906744624A5073907626 @default.
• W2906744624 hasAuthorship W2906744624A5076077834 @default.
• W2906744624 hasAuthorship W2906744624A5086557136 @default.
• W2906744624 hasBestOaLocation W29067446241 @default.
• W2906744624 hasConcept C104397665 @default.
• W2906744624 hasConcept C11960822 @default.
• W2906744624 hasConcept C185592680 @default.
• W2906744624 hasConcept C203014093 @default.
• W2906744624 hasConcept C2776414213 @default.
• W2906744624 hasConcept C2777938653 @default.
• W2906744624 hasConcept C2778461978 @default.
• W2906744624 hasConcept C2779878957 @default.
• W2906744624 hasConcept C42362537 @default.
• W2906744624 hasConcept C502942594 @default.
• W2906744624 hasConcept C55493867 @default.
• W2906744624 hasConcept C62478195 @default.
• W2906744624 hasConcept C86803240 @default.
• W2906744624 hasConcept C90059517 @default.
• W2906744624 hasConceptScore W2906744624C104397665 @default.
• W2906744624 hasConceptScore W2906744624C11960822 @default.
• W2906744624 hasConceptScore W2906744624C185592680 @default.
• W2906744624 hasConceptScore W2906744624C203014093 @default.
• W2906744624 hasConceptScore W2906744624C2776414213 @default.
• W2906744624 hasConceptScore W2906744624C2777938653 @default.
• W2906744624 hasConceptScore W2906744624C2778461978 @default.
• W2906744624 hasConceptScore W2906744624C2779878957 @default.
• W2906744624 hasConceptScore W2906744624C42362537 @default.
• W2906744624 hasConceptScore W2906744624C502942594 @default.
• W2906744624 hasConceptScore W2906744624C55493867 @default.
• W2906744624 hasConceptScore W2906744624C62478195 @default.
• W2906744624 hasConceptScore W2906744624C86803240 @default.
• W2906744624 hasConceptScore W2906744624C90059517 @default.
• W2906744624 hasIssue "Supplement 1" @default.
• W2906744624 hasLocation W29067446241 @default.
• W2906744624 hasOpenAccess W2906744624 @default.
• W2906744624 hasPrimaryLocation W29067446241 @default.
• W2906744624 hasRelatedWork W1780111622 @default.
• W2906744624 hasRelatedWork W1982769358 @default.
• W2906744624 hasRelatedWork W2006528910 @default.
• W2906744624 hasRelatedWork W2172629347 @default.
• W2906744624 hasRelatedWork W2984292213 @default.
• W2906744624 hasRelatedWork W3021709493 @default.
• W2906744624 hasRelatedWork W3174994842 @default.
• W2906744624 hasRelatedWork W3212253138 @default.
• W2906744624 hasRelatedWork W956985056 @default.
• W2906744624 hasRelatedWork W2475047365 @default.
• W2906744624 hasVolume "132" @default.
• W2906744624 isParatext "false" @default.
• W2906744624 isRetracted "false" @default.
• W2906744624 magId "2906744624" @default.
• W2906744624 workType "article" @default.